Relapsed And Or Refractory Chronic Lymphocytic Leukemia Cll Small Lymphocytic Lymphoma Sll clinical trials

Explore recruiting relapsed and or refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma sll clinical trials.

Recruiting relapsed and or refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma sll studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed And Or Refractory Chronic Lymphocytic Leukemia Cll Small Lymphocytic Lymphoma Sll trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (SACRED).

Hungary, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Relapsed And Or Refractory Chronic Lymphocytic Leukemia Cll Small Lymphocytic Lymphoma Sll trials by city

Relapsed And Or Refractory Chronic Lymphocytic Leukemia Cll Small Lymphocytic Lymphoma Sll clinical trials

Recruiting relapsed and or refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma sll studies right now

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Also recruiting in Europe

A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (SACRED).

Relapsed And Or Refractory Chronic Lymphocytic Leukemia Cll Small Lymphocytic Lymphoma Sll trials by city

Other conditions